peptidylglycine alpha-amidating monooxygenase enzyme therapy

Peptidylglycine alpha-amidating monooxygenase (PAM) enzyme therapy refers to the therapeutic use or replacement of the PAM enzyme, which is essential for the post-translational modification of peptide hormones and neuropeptides. The PAM enzyme catalyzes the conversion of glycine-extended peptides into amidated peptides by a two-step process involving its two domains—peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL). This C-terminal amidation is critical for full biological activity, stability, and receptor binding of many signaling peptides such as oxytocin, vasopressin, and neuropeptide Y. Deficiency or dysfunction in this pathway can disrupt endocrine and neuronal signaling[1][2][6]. While inhibitors targeting this pathway are being explored for cancer or psychiatric disorders[2][3], there is currently no marketed recombinant or exogenous "PAM enzyme therapy" as an approved drug; however, such a modality would be classified as an experimental form of Enzyme Replacement Therapy aimed at restoring normal peptide amidation in cases where endogenous activity is deficient.

Other names

peptidylglycine alpha-amidating monooxygenase enzyme therapyPAM replacement therapyPAM ERT